glp-1 and family history of thyroid cancer receptor agonist use for more than 1 year may increase risk Risk of pancreatic cancer associated

FOR LOSE COVERAGE SOURCE: American Medical Association

NEJM peer review matters here because it compels the oncology and neuroendocrinology communities not just rare-disease specialists to engage with the evidence on its own terms

PLEASE NOTE: The information provided on this page is intended for general informational purposes only

Castel Santana, regional medical director at 10X Health, a health and wellness company that offers peptides, said that he feels confident that most peptides have minimal or low associated risk based on his personal experiences prescribing them

Tirzepatide and semaglutide can have the unfortunate side effect of potential muscle loss alongside their therapeutic effectsparticularly if youre on a long-term weight loss plan

Energy expenditure decreases